Here, we show that administering an anti-OX40 antibody at various intervals prior to definitive surgical resection in 17 patients with stage II-IVA HNSCC (Clinical Trial ID#NCT02274155) is safe. Here, TNFRSF4 is linked to head and neck squamous cell carcinoma.